fbpx
QQQ
+ 2.03
333.05
+ 0.61%
DIA
+ 2.82
332.25
+ 0.84%
SPY
+ 3.01
405.47
+ 0.74%
TLT
-0.50
138.51
-0.36%
GLD
-1.23
165.72
-0.75%

Avinger Technical Levels To Watch Following Patent News

March 2, 2021 5:17 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Avinger Technical Levels To Watch Following Patent News

Avinger Inc. (NASDAQ:AVGR) is forming what technical traders call a pennant on the daily chart below. The pennant is considered to be speculatively bullish because the large move that precedes the pennant goes upwards.

What Happened: In the case of Avinger, the large move originated from the news of a European Granted Patent on Dec. 30.

Avinger was awarded a U.S. patent for an optical pressure sensor assembly Tuesday. 

In theory, the highs and the lows should continue to be condensed as time goes on until the price gets “squeezed” out of the pennant and makes another large move.

The large move can go in either direction despite the fact that the pattern is considered bullish, so caution is always key in the play.

Avinger Technical Levels: At the top of the pennant, there are what technical traders call resistance, and at the bottom of the pennant you have what technical traders call support.

These technical levels are speculatively based on previous highs and lows on the chart. The speculative support and resistance lines are currently trading between the price range of $1.50 and $2 and will continue to be condensed until the stock will “break out” of the price range.

Ideally, bullish technical traders would like to see a break of resistance and a price consolidation above the speculative resistance before another move up.

Ideally, bearish technical traders would like to see the price fall through support and consolidate below before a further move down.

The market cap of Avinger is currently $146.41 million with a public float of 84.63 million shares.avgrdaily3-2-21.png


Related Articles

Benzinga's Top Upgrades, Downgrades For April 12, 2017

4 Biomedical Stocks Canaccord Loves

Last Week's Biotech IPO Recap

Two More Biotech IPO's Will Debut Friday, One Deal Pushed Out